TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07558733: Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Sponsor: Faeth Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,295,910

Rescue Site Savings

+$863,940

Unlock Full NCT07558733 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07558733 Rescue Dossier →